Erin Borger
Chief Executive Officer bei ExThera Medical Corp.
Profil
Erin R.
Borger is currently the Chief Executive Officer & Director at ExThera Medical Corp.
Mr. Borger previously worked as a Director at the National Parkinson Foundation, Inc. Mr. Borger also served as an Independent Director at Longeveron, Inc. Mr. Borger completed their undergraduate degree at Wofford College.
Aktive Positionen von Erin Borger
| Unternehmen | Position | Beginn |
|---|---|---|
ExThera Medical Corp.
 ExThera Medical Corp. Medical/Nursing ServicesHealth Services ExThera Medical Corp. develops medical devices that address unmet clinical needs in the treatment of bloodstream infections and pathogen-reduction in blood banking. The company develops Seraph Microbind Affinity Blood Filter (Seraph), which captures and removes normal and drug-resistant bacteria, viruses, toxins, and pro-inflammatory cytokines from human blood; and offers solution for use in a dialysis, such as extracorporeal circuit for treating existing bloodstream infections. The company was founded in 2007 and is headquartered in Martinez, CA. | Chief Executive Officer | 15.11.2023 |
Ehemalige bekannte Positionen von Erin Borger
| Unternehmen | Position | Ende |
|---|---|---|
| LONGEVERON INC. | Director/Board Member | 09.06.2023 |
| National Parkinson Foundation, Inc. | Director/Board Member | - |
Ausbildung von Erin Borger
| Wofford College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| LONGEVERON INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
| National Parkinson Foundation, Inc. | Health Technology |
ExThera Medical Corp.
ExThera Medical Corp. Medical/Nursing ServicesHealth Services ExThera Medical Corp. develops medical devices that address unmet clinical needs in the treatment of bloodstream infections and pathogen-reduction in blood banking. The company develops Seraph Microbind Affinity Blood Filter (Seraph), which captures and removes normal and drug-resistant bacteria, viruses, toxins, and pro-inflammatory cytokines from human blood; and offers solution for use in a dialysis, such as extracorporeal circuit for treating existing bloodstream infections. The company was founded in 2007 and is headquartered in Martinez, CA. | Health Services |
